Putting Financial House in Order, Accelrys Targets Downstream Development Market for Future Growth | GenomeWeb

Accelrys has filed a sheaf of records with the US Securities and Exchange Commission that should end a period of uncertainty for the firm in the wake of its December disclosure that it would have to restate its financial records for the past five years [BioInform 12-26-05].

Besides its historical restatement — which uncovered "weaknesses" in its accounting process — Accelrys this week filed its quarterly report for the three months ended Dec. 31, 2005, and its annual report for its fiscal year ended March 31, 2006.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.